Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d three years and older are planned to enroll in the trial, which is targeted to be conducted in 10 to 15 sites across the US, Europe and Canada. The study will comprise ABH001 applications sufficient to cover the surface area of the wound, applied topically every 4 weeks with protocol-specified dressings until healed or for up to 24 weeks.

"We are excited that Shire Regenerative Medicine has launched this trial," said Brett Kopelan , Executive Director of the Dystrophic EB Research Association of America (DebRA ) and father to a 5-year-old girl with recessive dystrophic EB.  "While there is currently no cure for EB, I am encouraged that ABH001 is…targeting the chronic wounds that are the hallmark of this disease. I applaud Shire for pushing this forward and look forward to working closely with them as the trial progresses."  

"We are very eager to begin evaluating ABH001 as a potential wound treatment option for people with EB. We believe it has the potential to initiate and continue wound healing in this patient population," said Jeff Jonas , MD, President of Shire Regenerative Medicine. "We are committed to developing regenerative medicine solutions that enable people with life-altering conditions to lead better lives, and are encouraged by the fast track and orphan drug designations we have received to further develop this potential therapy for people, most often young children, suffering from this devastating condition."

Shire is also developing an intravenous protein replacement therapy for the treatment of dystrophic EB, which the company's Human Genetic Therapies business recently acquired from Lotus Tissue Repair, Inc. Initiation of this pivotal trial of ABH001 for patients with EB further demonstrates Shire's commitment to developing a portfolio of products targeted toward patients who suffer from this di
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report defines and ... and forecast of revenue. This market is estimated to ... by 2019, at a Compound Annual Growth Rate (CAGR) ... the TOC of the Asia-Pacific Speech Analytics market report ... It also provides a glimpse of the segmentation in ...
(Date:10/18/2014)... (PRWEB) October 19, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers, restraints, challenges, opportunities, current market trends, ... along with the estimates and forecasts of the ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The Asia-Pacific ... and segments the concerned market in Asia-Pacific with analysis ... $72.6 million in 2013, and is expected to reach ... from 2013 to 2018. , Browse through the TOC ... an idea of the in-depth analysis provided. This also ...
(Date:10/18/2014)... The “Global Diagnostic Electrocardiograph (ECG) ... End-user (Hospitals, Home/Ambulatory, Research Center, Physician Office, Nursing ... Forecast to 2020” provides a detailed overview of ... trends, and strategies impacting the global diagnostic ECG ... the revenue and share analysis. , The global ...
Breaking Biology Technology:The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5
... (Nasdaq: DNDN ) announced today the closing of ... its common stock, which shares were offered for sale to ... 2009, Deutsche Bank Securities Inc., acting as sole manager of ... an additional 1,279,166 shares of common stock at the public ...
... Microtest Laboratories , a leading single ... to its current suite of analytical testing ... of dissolution testing is the perfect ... President and Scientific Founder of Microtest Laboratories ( www.microtestlabs.com ...
... Italy, May 13 The FDA has approved ... Sciences to,begin a phase I clinical study with ... of cancer. PLK-1 is a mitotic kinase required ... is orally bioavailable,highly efficient and well tolerated in ...
Cached Biology Technology:Dendreon Announces Closing of Common Stock Offering 2Dendreon Announces Closing of Common Stock Offering 3Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 2Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 3Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor 2
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... will be awarded the 44th Rosenstiel Award for Distinguished ... pioneering research exploring the mechanisms of genomic instability and ... Alt is the second alumnus to win the Rosenstiel ... in 2003. , Alt is the Charles A. Janeway ... Medical School and an investigator at the Howard Hughes ...
(Date:10/14/2014)... 14, 2014)—It,s been millions of years since T. ... led by Ohio University scientists is breathing life back ... through dinosaur snouts. The research has important implications for ... but to enhance the sense of smell and cool ... said Ohio University doctoral student Jason Bourke, lead author ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... researchers have,automatically grouped fluorescently tagged proteins from,high-resolution ... a new way to,identify disease proteins and ... cluster together inside a cell.,The approach, developed ... to localize proteins inside cells, says,Professor Robert ...
... California, San Diego have invented a process to ... specialized cells being sought as possible,treatments for dozens ... Shu Chien, UCSD bioengineering professors, and Christopher,J. Flaim, ... a paper published in the February issue of ...
... Nanosphere, Inc. today reported unprecedented benefits in the ... Nanosphere's nanoparticle-based technology allows for rapid, highly-sensitive and specific ... the direct detection of a particular gene and the ... technology, reported in the February 2005 (Volume 33, Number ...
Cached Biology News:New, automated tool successfully classifies and relates proteins in unprecedented way 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Novel technology detects human DNA mutations 2
... The ISOQUANT(R) Isoaspartate Detection Kit is intended ... in proteins and peptides, which can result ... or rearrangement of aspartic acid residues during ... not depend on the monitoring of charge ...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Rabbit polyclonal to EDG2 ( Abpromise for all tested applications). entrezGeneID: 1902 SwissProtID: Q92633...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Biology Products: